Pulsenmore Expands Fertility Platform into UK with MHRA Registration
Event summary
- Pulsenmore Ltd. has completed MHRA registration for its Pulsenmore FC home ultrasound system, enabling marketing in the UK and Northern Ireland.
- The system is designed for follicular and endometrial monitoring during IVF and fertility preservation treatments, with remote guidance from healthcare professionals.
- The UK fertility market saw over 100,000 IVF and fertility treatment cycles in 2024, with 53,000 patients undergoing IVF.
- Pulsenmore FC is the company's second product to reach international markets, following its home ultrasound system for pregnancy monitoring.
The big picture
Pulsenmore's expansion into the UK fertility market with its home ultrasound system reflects a broader trend towards remote monitoring and telemedicine in women's healthcare. The company's technology aims to reduce the need for repeated clinic visits, aligning with the growing demand for more convenient and patient-centric fertility treatments. The UK's significant and growing fertility market, with over 100,000 treatment cycles in 2024, presents a substantial opportunity for Pulsenmore to scale its platform.
What we're watching
- Market Penetration
- How Pulsenmore will position Pulsenmore FC against established fertility clinics and other remote monitoring solutions in the UK.
- Regulatory Compliance
- Whether Pulsenmore can maintain regulatory compliance as it expands into additional countries with significant IVF and fertility preservation cycles.
- Execution Risk
- The pace at which Pulsenmore can integrate its technology into fertility clinics' existing treatment pathways and gain clinician adoption.